Sales 2024 * | 76.08M 6.35B | Sales 2025 * | 68.35M 5.7B | Capitalization | 325M 27.13B |
---|---|---|---|---|---|
Net income 2024 * | -155M -12.94B | Net income 2025 * | -170M -14.19B | EV / Sales 2024 * | 2.76 x |
Net cash position 2024 * | 115M 9.58B | Net cash position 2025 * | 281M 23.49B | EV / Sales 2025 * | 0.64 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-2.49
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.63% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 01/07/01 |
Robert Chess
CHM | Chairman | 66 | 01/91/01 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 01/10/01 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 01/00/01 |
Robert Chess
CHM | Chairman | 66 | 01/91/01 |
1st Jan change | Capi. | |
---|---|---|
+31.01% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.92% | 239B | |
+10.18% | 210B | |
-6.91% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |